Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004737
Chunk: 2

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 2
---
 its Total Revenue and Core EPS guidance 5 for FY 2025 at CER, based on the average foreign exchange rates through 2024.

<div align='center'>Total Revenue is expected to increase by a high single-digit percentage

Core EPS is expected to increase by a low double-digit percentage</div>

- The Core Tax rate is expected to be between 18-22%

- If foreign exchange rates for April 2025 to December 2025 were to remain at the average rates seen in March 2025, it is anticipated that compared to the performance at CER, FY 2025 Total Revenue would incur a low single-digit percentage adverse impact (unchanged from prior guidance), and Core EPS would incur a low single-digit percentage adverse impact (previously mid single-digit).

Results highlights

Table 1. Milestones achieved since the prior results announcement

Phase III and other registrational data readouts

| Medicine      | Trial             | Indication                                                       | Event                                             |
| Enhertu       | DESTINY-Gastric04 | HER2-positive gastric/GEJ cancer (2nd-line)                      | Primary endpoint met                              |
| Enhertu       | DESTINY-Breast09  | HER2-positive metastatic breast cancer (1st line)                | Primary endpoint met for combination arm          |
| Imfinzi       | MATTERHORN        | Resectable gastric/GEJ cancer                                    | Primary endpoint met                              |
| camizestrant  | SERENA-6          | HR+ HER2- metastatic breast cancer (1st line switch on emergence 
 ofESR1m)                                                         | Primary endpoint met                              |
| eneboparatide | CALYPSO           | Chronic hypoparathyroidism                                       | Primary endpoint met, trial continues to 52 weeks |

Regulatory approvals

| Medicine              | Trial            | Indication                                           | Region |
| Calquence             | ACE-LY-004       | Relapsed/refractory MCL                              | EU     |
| Calquence             | ChangE           | CLL/SLL                                              | CN     |
| Datroway              | TROPION-Breast01 | HR+ HER2- breast cancer (2nd-line)                   | EU     |
| Enhertu               | DESTINY-Breast06 | HER2-low and -ultralow HR+ breast cancer (2nd-line+) | EU     |
| Imfinzi               | AEGEAN           | Resectable early